NCT03583697COMPLETEDanonymous

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of BMN 111 in Infants and Young Children With Achondroplasia, Age 0 to < 60 Months

Sponsor

Source record

BioMarin Pharmaceutical

Phase

Source record

PHASE2

Modality

AI-normalized

small molecule

Target

AI-normalized

BMN 111, Placebo

Indication / condition

AI-normalized

Achondroplasia

Intervention

Source record

BMN 111, Placebo

Related intelligence directories

Indication directory: Achondroplasia Modality directory: small molecule Target directory: BMN 111

Source & freshness

Source record

NCT ID

NCT03583697

Original source

ClinicalTrials.gov

Source last updated

Jun 13, 2024

Ingested at

Jun 11, 2026

Internal sync

Jun 11, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT03583697

Title

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of BMN 111 in Infants and Young Children With Achondroplasia, Age 0 to < 60 Months

Sponsor

BioMarin Pharmaceutical

Status

COMPLETED

Phase

PHASE2

Condition raw

Achondroplasia

Condition normalized

Achondroplasia

Modality raw

small molecule

Modality normalized

small molecule

Target raw

BMN 111, Placebo

Target normalized

BMN 111, Placebo

Interventions

BMN 111, Placebo

Public preview

Source record

Study 111-206 is a Phase 2 randomized, double-blind, placebo-controlled clinical trial of BMN 111 in infants and young children with a diagnosis of achondroplasia.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Early access offer

Subscribe with code FOUNDERS5 for a 5-day premium trial.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of BMN 111 in Infants and Young Children With Achondroplasia, Age 0 to < 60 Months

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 20, 2026

NCT ID

NCT03583697

Status

COMPLETED

Phase

PHASE2

Sponsor

BioMarin Pharmaceutical

Executive brief

Investment-Ready Snapshot

Study 111-206 is a Phase 2 randomized, double-blind, placebo-controlled clinical trial of BMN 111 in infants and young children with a diagnosis of achondroplasia.

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedJun 13, 2024

Internal syncJun 11, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT03583697

Indication

Achondroplasia

Modality

small molecule

Target

BMN 111, Placebo

Intervention

BMN 111, Placebo

Source record